# Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is an Asset Manager.

## Overview

- **Organization type:** Asset Manager
- **Assets under management:** Undisclosed
- **Website:** dermata.com
- **LinkedIn:** https://www.linkedin.com/company/dermata-therapeutics-inc

## Regulatory record

- **Reports private funds:** No

## About

Dermata Therapeutics, Inc. emerged from public filings as a corporate entity, but no founder, founding year, or wealth origin is publicly documented. The firm's sole disclosed focus is dermatological therapeutics, with a single drug candidate (DMT-01) referenced in regulatory filings and clinical trial registries. The firm's strategy concentrates on advancing this compound through Phase I/II trials for conditions including acne vulgaris and rosacea, relying on external capital raises rather than an existing asset pool. No asset-class mix, fund structure, or co-investment relationships have been disclosed, and the firm's geographic footprint — if any — is unstated. Dermata has no known team size, additional offices, adjacent vehicles, or philanthropic structures. The last 24 months have produced no operational events beyond routine SEC filings and a small public offering of common stock in November 2024 (per SEC filings, Q4 2024). The firm's structural differentiator is its singularity: it functions as a single-asset vehicle with no diversification, no management team publicly identified, and no track record of capital deployment beyond R&D. This architecture is closer to a shell company than to a typical biotech fund or family office.

## Sectors

- Biotech
- Pharmaceuticals

## Questions

### Who manages Dermata Therapeutics?

No named management team or investment professionals are publicly linked to Dermata Therapeutics. The firm's SEC filings list only a corporate officer, but no investment decision-maker is identified (per SEC records).

### Does Dermata Therapeutics make direct investments or deploy capital externally?

No. The firm's sole use of capital is internal R&D spending on DMT-01. It has no publicly recorded direct investments, co-investments, or external GP commitments (public record).

### How is Dermata Therapeutics different from a typical biotech fund?

A standard biotech fund diversifies across multiple portfolio companies or stages. Dermata Therapeutics holds a single asset, has no disclosed management team, and has no track record of capital deployment beyond its own R&D budget — it resembles a development-stage shell more than a fund.

## Related profiles

- [ADIAL Pharmaceuticals](https://altss.com/profile/adial-pharmaceuticals-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/dermata-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology